Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from a fruit – including berry
Reexamination Certificate
2000-05-25
2009-12-15
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from a fruit , including berry
C424S184100
Reexamination Certificate
active
07632528
ABSTRACT:
The novel Synergistic pharmaceutical composition for prophylactic treatment of migraine comprising of aqueous extracts ofSapindus trifoliatusandEmblica officinalisin combination with pharmaceutically acceptable selective additives and process for manufacturing the same. The formulation of the invention is stable and effective in prophylactic treatment of migraine. The Synergistic composition is obtained in the form of aqueous nasal drops for effective prophylactic treatment of migraine which would be safe without any harmful side effect and in particular would avoid/reduce chances of damage/irritation to the nasal mucus membrane when administered nasally. The present invention also provides for method of prophylactic treatment of migraine by administration of the Synergistic formulation comprising aqueous extract ofSapindus trifoliatusandEmblica officinalisin combination with selected pharmaceutically acceptable additives in the form of nasal drops.
REFERENCES:
http://www.shamanictonics.com/tonics/msm.html.
http://www.healthtouch.com.
http://www.AyurvedioCure.com.
Water, W.E., “The Prevalence of Migraine”,Headache, Mar. 1978, pp. 53-54.
Stewart, W.F. et al., “Migraine prevalence”,Neurology44, Jun. 1994, pp. S17-23.
Newman, L. C. et al., “Hemicrania Continua: Attacks May Alternate Sides”,Headache32, 1992, pp. 237-328.
Stewart, W.F. et al., “Prevalence of Migraine Headache in the United States”,JAMA, vol. 267, No. 1, Jan. 1, 1992, pp. 64-69.
Ishaq, A. A. et al., “Prevalence of headache and migraine in schoolchildren”,British Medical Journal, vol. 309, Sep. 24, 1994, pp. 765-769, Abu-Arefeh, I et al.
Ziegler, D. K. et al., “Headache syndromes suggested by statistical analysis of headache symptoms”,Cephalgia2, 1982, pp. 125-134.
Stewart, W. F. et al., “Migraine headache: epidemiology and health care utilization”,Cephalgia(Suppl. 12), 1993, pp. 41-46.
De Lissovoy, G. & Lazarus, S. S., “The economic cost of migraine”,Neurology44, Jun. 1994, pp. S56-S62, 44 (4).
Olesen, J. et al., “Spreading Cerebral Oligemia in Classical- and Normal Cerebral Blood Flow in Common Migraine”,Headache22, Nov. 1982, pp. 242-248.
Olesen, J. et al., “The Common Migraine Attack May Not Be Initiated by Cerebral Ischemia”,Lancet, Aug. 1981, pp. 438-440.
Raskin, N. H., “On the origin of Head Pain”,Headache28, May 1988, pp. 254-257.
Silberstein, S.D., “Advances in understanding the pathophysiology of headache”,Neurology42 (Suppl. 2), Mar. 1992, pp. 6-10.
Goadsby, P. J., “Localization of3H-Dihydroergotamine-binding Sites in the Cat Central Nervous System: Relevance to Migraine”,Annals of Neurology, vol. 29, Jan. 1991, pp. 91-94.
Weiler, C. et al., “Brain stem activation in spontaneous human migraine attacks”,Nature Medicine, vol. 1, No. 7, Jul. 1995, pp. 658-660.
Silberstein, S.D., “Serotonin (5-HT) and Migraine”,Headache34, Jul./Aug. 1994, pp. 408-417.
Moskowitz, M. A., “The Neurobiology of Vascular Head Pain”,Annals of Neurology, vol. 16, No. 2, Aug. 1984, pp. 157-168.
Peroutka, S.J. , “Dopamine and migraine”,Neurology49, Sep. 1997, pp. 650-656.
Headache Classification Committee of 10 HS,Cephalgia8 (Suppl. 7), Aug. 1988, pp. 1-96.
Ross-Lee, L. et al., Aspirin treatment of migraine attacks: clinical observations,Cephalgia2, 1982, pp. 71-76.
Peters, B. H. et al., “Comparison of 650 mg Aspirin and 1,000 mg Acetaminophen with Each Other, and with Placebo in Moderately Severe Headache”,American Journal of Medicine, Jun. 14, 1983, pp. 36-42.
Mathew, N.T., “Drug Induced Refractory Headache—Clinical Features and Mangement”,Headache, Oct. 1990, pp. 634-638.
Nestvold, K. et al., “Treatment of acute migraine attack: naproxen and placebo compared”,Cephalgia5, 1985, pp. 115-119.
Havanka Kanniainen H., “Treatment of Acute Migraine Attack: Ibuprofen and Placebo Compared”,Headache, 1989, pp. 507-509.
Klapper, J. A. et al., “Ketorolac Versus DHE and Metoclopramide in the Treatment of Migraine Headaches”,Headache31, Sep. 1991, pp. 523-524.
Welch, K. M. A., “Drug Therapy of Migraine”,The New England Journal of Medicine, Nov. 11, 1993, pp. 1476-1483.
American Academy of Neurology, “Practice parameter: Appropriate use of ergotamine tartrate and dihydroegotamine in the treatment of migraine and status migrainosus”,Neurology45, Mar. 1995, pp. 585-587.
Sanders, S.W. et al., “Pharmacokinetics of Ergotamine in Healthy Volunteers Following Oral and Rectal Dosing”,Eur. J. Clin. Pharmacol30, 1986, pp. 331-334.
Meyler, W. J., “Side effects of ergotamine”,Cephalgia16, 1996, pp. 5-10.
Callaham, M. et al., “A Controlled Study of Dihydroergotamine in the Treatment of Acute Migraine Headache”,Headache26, Apr. 1986, pp. 168-171.
Anzola, G.P. et al., “Abnormal Photoreactivity in lctal Migraine: Reversal by Sumatriptan”,Headache33, 1993, pp. 417-420.
Raskin, N. H., “Repetitive intravenous dihydroergotamine as therapy for intractable migraine”,Neurology36, Jul. 1986, pp. 995-997.
Mathew, N.T., “Serotonin 1D(5-HTID) Agonists and Other Agents in Acute Migraine”,Neurologic Clinics, vol. 15, Feb. 1997, pp. 61-83.
The Oral Sumatriptan International Multiple-Dose Study Group, “Evaluation of a Multiple-Dose Regimen of Oral Sumatriptan for the Acute Treatment of Migraine”,Eur. Neurol.31, 1991, pp. 306-313.
Cady, R. K. et al., “Treatment of Acute Migraine with Subcutaneous Sumatriptan”,JAMA, vol. 265, No. 21, Jun. 5, 1991, pp. 2831-2835.
Goadsby, P. J. et al., “Oral sumatriptan in acute migraine”,Lancet, vol. 338, Sep. 28, 1991, pp. 782-783.
Gross, M. L. P. et al., “Sumatriptan in Acute Migraine Using a Novel Cartridge System Self-Injector”,Headache34, Nov./Dec. 1994, pp. 559-563.
Bates, D. et al., “Subcutaneous sumatriptan during the migraine aura”,Neurology44, Sep. 1994, pp. 1587-1592.
The Subcutaneous Sumatriptan International Study Group, “Treatment of Migraine Attacks with Sumatriptan”,The New England Journal of Medicine, vol. 325, No. 5, pp. 316-321.
Simmons, V. E., et al., “The Safety Profile of Sumatriptan”,Rev. Contemp. Pharmachother.5, 1994, pp. 319-328.
Hillis, W. S. et al., “Drug Reactions, Sumatriptan and chest pain”,Lancet, vol. 341, Jun. 19, 1993, pp. 1564-1565.
Kubacka, R. T., “Practical Approaches to the Management of Migraine”,American Pharmacy, vol. NS 34, No. 5, May 1994, pp. 34-39, 43-44 and 73.
Moskowitz, M. A., “Basic Mechanisms in Vascular Headaches”,Neurol. Clinics, vol. 8, No. 4, Nov. 1990, pp. 801-815.
Jensen, K., “Extracranial tissues and nociceptive pathways”,Acta. Neurol. Scant.(Suppl. 147), 1993, pp. 1-27.
L. C. Newman et al., “Hemicrania Continua: Attacks May Alternate Sides”,Headache32, 1992, pp. 237-238.
V. L. Perrin, “Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache”,Clinical Pharmacokinetics10, 1985, pp. 334-352.
C. Hart, “Drugs for Migraine”,Modern Drug DiscoveryMar./Apr. 1999, pp. 20-31.
S. D. Silberstein, “The Pharmacology of Ergotamine and Dihydroergotamine”,Headache37, 1997, pp. S15-S25.
B. T. Horton et al., “A New Product in the Treatment of Migraine: A Preliminary Report”,Staff Meetings of the Mayo Clinic, vol. 20, 1945, pp. 241-248.
S. J. Peroutka, “The Pharmacology of Current Anti- Migraine Drugs”,Headache30, 1990, pp. 4-11.
S. Diamond et al., “Headaches”,Clinical Symposiavol. 41, 1989, pp. 1-32.
S. Diamond, “The use of sumatriptan in patients on monoamine oxidase inhibitors”,Neurology45, 1995, pp. 1039-1040.
J. T. Osterhaus et al., “Healthcare Resource and Lost Labour Costs of Migraine Headache i
Chikara Jitendra
Gupta Desh Bandhu
Lupin Limited
Mondesi Robert B
Tongue Lakia J
Westerman Hattori Daniels & Adrian LLP
LandOfFree
Antimigraine combination comprising Sapindus and Emblica... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antimigraine combination comprising Sapindus and Emblica..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimigraine combination comprising Sapindus and Emblica... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4066070